Immune Response, Viru-Tech Ltd. deal

The companies agreed to develop and distribute IMNR's Remune HIV immunoconjugate in South and Central America. Viru-Tech invested $3 million in IMNR, purchasing 235,000 shares at $12.77, a 50 percent ...